Updated:
Solve FSHD
The future of genetic medicine is epic. | Epicrispr Biotechnologies is a biotechnology company developing ultracompact therapies to modulate gene expression in...
Solve FSHD
The future of genetic medicine is epic. | Epicrispr Biotechnologies is a biotechnology company developing ultracompact therapies to modulate gene expression in vivo using the smallest known Cas protein, CasMINI.
General information
Firm type
Venture Philanthropy
Year founded
2021
AUM
$100M (firm disclosure)
Location
Region
North America
Country
Canada
City
Vancouver
Corporate office
Vancouver, British Columbia, Canada
Principals
Chip Wilson
Founder & Chairman of the Board
Neil Camarta
Board Member and Co-Founder
Eva R. Chin
Executive Director
Sector focus
Frequently asked questions
Who runs investment decisions at Solve FSHD?
Executive Director Eva R. Chin leads the management team and day-to-day operations, including grant and partnership selection. Scientific decisions are guided by a Scientific Advisory Board of FSHD experts, and the Board of Directors — chaired by Chip Wilson — provides strategic oversight. No external investment committee is involved; capital is deployed directly through the organization's grant and collaboration structure.
Does Solve FSHD participate in fund commitments or only direct deals?
Solve FSHD makes direct grants and enters into strategic collaborations — it does not commit to external investment funds. Its model is analogous to a venture investor, but it funds research and development directly through partnerships with academic labs, biotech companies, and clinical trial sites. The Modalis collaboration is an example of an R&D partnership, not a financial investment.
Which sectors does Solve FSHD explicitly avoid?
Solve FSHD only funds research and development directly related to FSHD — it avoids all other therapeutic areas and asset classes. The organization does not invest in real estate, public equities, venture capital funds, or non-FSHD biotech. Its entire mandate is focused on curing facioscapulohumeral muscular dystrophy.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: